07:00 , Mar 17, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Brain-derived neurotrophic factor (BDNF); neurotrophic tyrosine kinase receptor 2 (TrkB; NTRK2); excision repair cross-complementation group 6 (ER

Neurology INDICATION: Leukodystrophy Patient sample and cell studies suggest BDNF, BDNF mimetics or other agonists of its receptor, TrkB, could help treat Cockayne syndrome, a leukodystrophy caused by ERCC6 mutations that is associated with defects in neurogenesis...
08:00 , Dec 23, 2013 |  BC Week In Review  |  Clinical News

TC-5619: Development discontinued

Targacept discontinued development of TC-5619 to treat negative symptoms and cognitive dysfunction in patients with schizophrenia after top-line data from a double-blind, international Phase IIb trial in 477 patients with schizophrenia showed that once-daily 5...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Clinical News

Aggrastat tirofiban regulatory update

Medicure submitted an sNDA to FDA to expand the label of Aggrastat tirofiban to include a high-dose regimen consisting of an initial bolus of 25 µg/kg Aggrastat and then continued at 0.15 µg/kg/min. The non-peptide...
07:00 , Mar 24, 2011 |  BC Innovations  |  Tools & Techniques

Aspiring cancer diagnostic

Massachusetts researchers have developed portable NMR technology that uses fine needle aspirates to help scientists diagnose cancer more quickly and accurately than is possible with conventional tumor biopsies.1 Although the technology could confirm the results...
07:00 , Oct 6, 2008 |  BC Week In Review  |  Company News

Cellumen, Alzheimer's Drug Discovery Foundation deal

Cellumen received undisclosed funding from the foundation to create a cellular model of Alzheimer's disease. Cellumen will use its Cellular Systems Biology (CSB) technology to develop a panel of assays and biosensors to determine target...